-
Case evaluation Professor Hou Ming: The combination of two swords and walls has begun to show strength, the blade out of the sheath to accurately block elderly AML, and the treatment of FLT3 mutant AML by geratinib can be expected in the future
Time of Update: 2023-01-06
05×10 9/L, HGB 54g/L, PLT 7×109/L, combined with pulmonary infection, cardiac insufficiency, treated with meropenem, tigecycline, voriconazole, improved, and considered adjusting the 。Myelocytology: CRFlow cytometry: abnormal myeloid cells < 0.
-
The innovative CD20 monoclonal antibody set sail in the wave of standardized treatment of indolent lymphoma
Time of Update: 2023-01-06
▎Professor Zhang Qingyuan:In the clinical treatment of FL, obinutuzumab has a wealth of evidence-based medical evidence, including the GALLIUM study is a global multicenter, randomized controlled phase III study comparing the efficacy of obinutuzumab in combination with chemotherapy (G-chemotherapy group) and rituximab plus chemotherapy regimen (R-chemotherapy group) in induction therapy in patients with treatment-naïve FL 。 Results showed that the G-chemotherapy regimen significantly improved PFS (3-year PFS rate 80.
-
Professor Chen Li: Public report! Celiniso in combination with chemotherapy has been shown to bring effective remission in patients with relapsed/refractory plasmablastic lymphoma
Time of Update: 2023-01-06
Poke "Read Original" to see moreBased on the mechanism of action of celinisol, its broad-spectrum anti-tumor effect and synergistic effect with a variety of chemotherapy drugs, Professor Chen Li's team applied celiniso combined with GDP chemotherapy to patients with PBL, and sorted out the specific cases and published them in the Journal of Clinical Hematology, which is also the first public report on the treatment of PBL by celiniso.
-
Professor Qiu Lin: Dynamic monitoring of mutant genes, NGS to help AML personalized precision treatment| the 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
Next-generation sequencing (NGS) plays an important role in the prognosis analysis, efficacy evaluation, recurrence prediction and detection of minimal residual disease (MRD) in acute myeloid leukemia
-
【Lymphoma diagnosis and treatment talent construction project】Appeared at the Takeda booth at CIIE to help achieve the goal of "2030 Healthy China"
Time of Update: 2023-01-06
In line with the call of the times, the lymphoma diagnosis and treatment talent construction project sponsored by the Chinese Health Science and Technology Promotion Association has been successfully launched with the cooperation of all parties, which is committed to cultivating lymphoma diagnosis and treatment talents, establishing lymphoma demonstration centers (COE) and lymphoma diagnosis and treatment pathways, helping clinicians improve the level of diagnosis and treatment, improve the cure rate of lymphoma in China, and benefit more Chinese lymphoma patients.
-
Professor Liu Peng from HEMA perspective: RWS in China has identified the benefits of anti-CD20 monoclonal antibody maintenance therapy, providing new evidence for the optimization of FL treatment
Time of Update: 2023-01-06
1Yimaitong: It is understood that your Chinese Academy of Medical Sciences Cancer Hospital Internal Medicine-Lymphoma Treatment Team conducted a real-world study (RWS) with more than 5 years of follow-up for the first time in the era of rituximab in the era of advanced FL in China, and explored the impact of anti-CD20 monoclonal antibody maintenance therapy on patients' treatment outcomes.
-
Efficacy of Midostaurin in combination with intensive chemotherapy in young and elderly patients with AML with FLT3-ITD mutations
Time of Update: 2023-01-06
In a randomized Phase 3 pivotal CALGB 10603 (RATIFY) trial comparing placebo, patients aged 18 to 59 years with newly diagnosed AML with FLT3 mutation experienced significant improvements in overall survival (OS) and event-free survival (EFS) after receiving midostaurin plus intensive chemotherapy sequential 1-year midostaurin maintenance therapy.
-
Efficacy of Midostaurin in combination with intensive chemotherapy in young and elderly patients with AML with FLT3-ITD mutations
Time of Update: 2023-01-06
In a randomized Phase 3 pivotal CALGB 10603 (RATIFY) trial comparing placebo, patients aged 18 to 59 years with newly diagnosed AML with FLT3 mutation experienced significant improvements in overall survival (OS) and event-free survival (EFS) after receiving midostaurin plus intensive chemotherapy sequential 1-year midostaurin maintenance therapy.
-
Professor Ying Zhitao: The road ahead is also bright, improve the efficacy of CAR-T, solve the dilemma of CAR-T cell therapy, and the 7th International Summit Forum on Anti-leukemia and Lymphoma is on the road
Time of Update: 2023-01-06
On the occasion of the "7th Anti-Leukemia and Lymphoma International Summit Forum and CSCO Leukemia & Lymphoma Expert Committee Tour - Harbin Station", Yimaitong is honored to invite Professor Ying Zhitao of Peking University Cancer Hospital to be interviewed to introduce the current status of CAR-T cell therapy in lymphoma treatment, and talk about the achievements and future exploration directions of the lymphoma department of Peking University Cancer Hospital (Beiwei).
-
Professor Huang Wenrong: Progress in first-line induction and consolidation therapy for primary central nervous system lymphoma The 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
Professor Huang Wenrong said that previous prospective studies have proved that ASCT and whole-brain radiotherapy can significantly improve the median progression-free survival (PFS) of patients with first-line therapy remission of PCNSL compared with non-myeloablative high-dose consolidation chemotherapy.
-
Professor Cai Qingqing: New drugs continue to emerge, where is the treatment of relapsed and refractory diffuse large B-cell lymphoma? The 7th International Summit Forum on Anti-Leukemia and Lymphoma
Time of Update: 2023-01-06
CAR-TCAR-T is an effective option for patients with R/R DLLBL who have failed R-CHOP, are not suitable for transplantation, or have failed HDC-ASCT 。 Current CD19-targeting CAR-T cell products for DLBCL include Axicabtagene ciloleucel (Axi-cel, ZUMA-1 study), Tisagenlecleucel (Tisa-cel, JULIET study), and Lisocabtagene maraleucel (Liso-cel, TRANSCEND study), at R/R Higher treatment was shown in all third-line and above treatments for DLBCL: ORR of 52-83% and CR rate of 40% to 58%.
-
Professor Cai Qingqing: New drugs continue to emerge, where is the treatment of relapsed and refractory diffuse large B-cell lymphoma? The 7th International Summit Forum on Anti-Leukemia and Lymphoma
Time of Update: 2023-01-06
CAR-TCAR-T is an effective option for patients with R/R DLLBL who have failed R-CHOP, are not suitable for transplantation, or have failed HDC-ASCT 。 Current CD19-targeting CAR-T cell products for DLBCL include Axicabtagene ciloleucel (Axi-cel, ZUMA-1 study), Tisagenlecleucel (Tisa-cel, JULIET study), and Lisocabtagene maraleucel (Liso-cel, TRANSCEND study), at R/R Higher treatment was shown in all third-line and above treatments for DLBCL: ORR of 52-83% and CR rate of 40% to 58%.
-
Professor Shen Zhixiang: Changes in the field of hematological oncology and suggestions for young doctors The 7th International Summit Forum on Anti-Leukemia and Lymphoma
Time of Update: 2023-01-06
In recent years, with the development of overall science, the field of hematological oncology has undergone earth-shaking changes, and the remission and prognosis of hematological cancer patients have
-
"Artificial red blood cells" are used in human trials for the first time! Or will revolutionize the treatment of patients with blood disorders!
Time of Update: 2023-01-06
The UK's National Health Service (NHS) has launched a clinical trial with research institutions such as the University of Bristol to inject laboratory-grown red blood cells into humans for the first time.
-
Luspatercept for the treatment of non-transfusion-dependent β-thalassemia
Time of Update: 2023-01-06
This article is from NEJM Journal WatchLuspatercept for Non-Transfusion-Dependent β-ThalassemiaLuspatercept for the treatment of non-transfusion-dependent β-thalassemiaReviewed by Brady Stein, MD, MHSLuspatercept increased hemoglobin concentration by at least 1 g/dL compared to placebo.
-
Meet Professor Hu Yu: Focus on the quality of life of MM and go to the road of PRO-oriented treatment optimization
Time of Update: 2023-01-06
Multiple myeloma (MM) is a malignant plasma cell disorder that accounts for approximately 10% of hematologic malignancies1. Although the emergence of new drugs and new therapies has improved the survi
-
Roche's "Blood Stars" shines in the Bo, gathering all parties to benefit Chinese blood disease patients
Time of Update: 2023-01-06
Professor Wu Depei, Chairman of the Hematology Society Branch of the Chinese Medical Association, pointed out: "Nowadays, the development of blood disease treatment is changing with each passing day, and innovative drugs are constantly emerging; The world's first CD79b-targeting antibody drug conjugate (ADC), vepotuzumab, which will be launched in China, is the biggest breakthrough in the field of lymphoma in the past 20 years and is expected to revolutionize the standard of clinical treatment.
-
Roche's "Blood Stars" shines in the Bo, gathering all parties to benefit Chinese blood disease patients
Time of Update: 2023-01-06
Professor Wu Depei, Chairman of the Hematology Society Branch of the Chinese Medical Association, pointed out: "Nowadays, the development of blood disease treatment is changing with each passing day, and innovative drugs are constantly emerging; The world's first CD79b-targeting antibody drug conjugate (ADC), vepotuzumab, which will be launched in China, is the biggest breakthrough in the field of lymphoma in the past 20 years and is expected to revolutionize the standard of clinical treatment.
-
The original intention is like a torch, hard work is like sail, leukemia and lymphoma special session 1 focuses on the frontier The Harbin branch of the 2022 CSCO Academic Annual Conference
Time of Update: 2023-01-06
Click to read the original article to see more conference videosProfessor Zhang Huilai of Tianjin Medical University Cancer Hospital gave a report entitled "The New Era of Lymphoma Immunotherapy: Breakthroughs and Challenges in Immune Checkpoint Research" from multiple dimensions such as immune dysregulation mechanism and immunotherapy methods.
-
Professor Georg Lenz: Exploring the revolution in DLBCL first-line treatment
Time of Update: 2023-01-06
Question 2: Before Pola reimbursement, what do you think is the most suitable treatment population for untreated DLBCL patients?Professor Georg LenzFrom subgroup analysis data, Pola-R-CHP regimens showed more significant benefit in patients with high-risk factors such as IPI score 3 to 5, age > 60 years, double expression, and ABC subtype, and may be biased towards these patients before reimbursement.
